Litigation Details for Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2018)
✉ Email this page to a colleague
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-02-06 |
| Court | District Court, D. Massachusetts | Date Terminated | 2018-09-27 |
| Cause | 28:2201 Declaratory Judgment | Assigned To | Allison Dale Burroughs |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 8,586,045 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
The biologic drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-09-27 | 23 | Memorandum & Order | infringement of five of the Teva Patents, U.S. Patent Nos. 8,586,045; 8,597,649; 9,266,951; 9,340,614;… Trademark Office (“USPTO”) issued U.S. Patent No. 8,586,045, entitled “Methods of Using Anti-CGRP Antagonist…infringement of those patents, in connection with two of the Teva Patents, U.S. Patent Nos. 9,884,907 and…claimed in a patent or the use of which is claimed in a patent before the expiration of such patent.”). As …several patents that are relevant to this dispute. On November 19, 2013, the United States Patent and Trademark | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
